Abstract：
UNASSIGNED: Intraplacental choriocarcinoma is a gestational trophoblastic neoplasia located within the placenta. Due to the usual silent presentation, more than half of the cases are diagnosed incidentally. It has been demonstrated that this pathology is linked to feto-maternal hemorrhage (FMH), stillbirth, and intrauterine growth restriction. The aim of our review was to establish if there are recurrent signs that might lead to an early diagnosis and better management in cases complicated by FMH.
UNASSIGNED: We performed a systematic review of the literature from 2000 up to March 2023. The adopted research strategy included the following terms: (gestational choriocarcinoma obstetrics outcome) AND (intraplacental choriocarcinoma) AND (gestational choriocarcinoma). The MEDLINE (PubMed), Google Scholar, and Scopus databases were searched.
UNASSIGNED: The research strategy identified 19 cases of FMH coexisting with intraplacental choriocarcinoma (IC), as described in 17 studies. The perinatal mortality rate was 36.8%. In eight cases, histological diagnosis of IC was made post-delivery. Metastatic lesions were found in 75% (6/8) of described cases. One case of maternal death has been described. Chemotherapy was necessary in seven cases. Sporadical prenatal ultrasound signs were described.
UNASSIGNED: The diagnosis of IC is usually delayed, mostly due to aspecific symptoms and signs. Histological analysis of the placenta, when not routinely performed, should be performed when warning symptoms are encountered. The maternal prognosis was good, with a mortality rate of 5.5%. A fertility-sparing approach is always possible even in the presence of metastasis. Chemotherapy seems to be useful in cases of maternal and neonatal metastasis.
UNASSIGNED: We performed a systematic review of the literature from 2000 up to March 2023. The adopted research strategy included the following terms: (gestational choriocarcinoma obstetrics outcome) AND (intraplacental choriocarcinoma) AND (gestational choriocarcinoma). The MEDLINE (PubMed), Google Scholar, and Scopus databases were searched.
UNASSIGNED: The research strategy identified 19 cases of FMH coexisting with intraplacental choriocarcinoma (IC), as described in 17 studies. The perinatal mortality rate was 36.8%. In eight cases, histological diagnosis of IC was made post-delivery. Metastatic lesions were found in 75% (6/8) of described cases. One case of maternal death has been described. Chemotherapy was necessary in seven cases. Sporadical prenatal ultrasound signs were described.
UNASSIGNED: The diagnosis of IC is usually delayed, mostly due to aspecific symptoms and signs. Histological analysis of the placenta, when not routinely performed, should be performed when warning symptoms are encountered. The maternal prognosis was good, with a mortality rate of 5.5%. A fertility-sparing approach is always possible even in the presence of metastasis. Chemotherapy seems to be useful in cases of maternal and neonatal metastasis.
摘要：
■胎盘内绒毛膜癌是位于胎盘内的妊娠滋养细胞瘤。由于通常的无声演讲，超过一半的病例是偶然诊断的。已经证明这种病理与胎儿母体出血（FMH）有关，死产,和宫内生长受限.我们审查的目的是确定是否有复发迹象可能导致FMH并发病例的早期诊断和更好的治疗。
■我们对2000年至2023年3月的文献进行了系统回顾。采用的研究策略包括以下术语：（妊娠绒毛膜癌产科结局）和（胎盘内绒毛膜癌）和（妊娠绒毛膜癌）。MEDLINE（PubMed），谷歌学者，搜索了Scopus数据库。
■研究策略确定了19例FMH与胎盘内绒毛膜癌（IC）并存，如17项研究所述。围产期死亡率为36.8%。在八个案例中，IC的组织学诊断是在分娩后进行的。在描述的病例中，有75％（6/8）发现了转移性病变。已经描述了一例产妇死亡病例。7例需要化疗。描述了零星的产前超声征象。
■IC的诊断通常会延迟，主要是由于特定的症状和体征。胎盘的组织学分析,当不是常规执行时，当遇到警告症状时，应执行。产妇预后良好,死亡率为5.5%。即使在存在转移的情况下，保留生育力的方法也总是可能的。化疗似乎对母体和新生儿转移的病例有用。
■我们对2000年至2023年3月的文献进行了系统回顾。采用的研究策略包括以下术语：（妊娠绒毛膜癌产科结局）和（胎盘内绒毛膜癌）和（妊娠绒毛膜癌）。MEDLINE（PubMed），谷歌学者，搜索了Scopus数据库。
■研究策略确定了19例FMH与胎盘内绒毛膜癌（IC）并存，如17项研究所述。围产期死亡率为36.8%。在八个案例中，IC的组织学诊断是在分娩后进行的。在描述的病例中，有75％（6/8）发现了转移性病变。已经描述了一例产妇死亡病例。7例需要化疗。描述了零星的产前超声征象。
■IC的诊断通常会延迟，主要是由于特定的症状和体征。胎盘的组织学分析,当不是常规执行时，当遇到警告症状时，应执行。产妇预后良好,死亡率为5.5%。即使在存在转移的情况下，保留生育力的方法也总是可能的。化疗似乎对母体和新生儿转移的病例有用。
